Skip to content

Study · Animal study (in vivo) · mouse · 2011

11 results

Central melanocortin receptor agonist reduces hepatic lipogenic gene expression in streptozotocin-induced diabetic mice.

Leckstrom A, Lew PS, Poritsanos NJ, Mizuno TM

Life sciences18 Feb 2011Cited by 14 (Europe PMC)

PMID21315740 (opens in a new tab)DOI10.1016/j.lfs.2011.01.026 (opens in a new tab)PepBankPUB-21315740
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII significantly reduced hepatic SCD1 mRNA expression.

    In plain wordsIn diabetic mice, MTII given into the brain lowered activity of the SCD1 fat-making gene in the liver.

    Peptide
    Melanotan II
    Outcome
    DecreaseHepatic SCD1 mRNA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    MTII treatment significantly reduced hepatic expression levels of genes encoding lipid biosynthetic enzymes, stearoyl-CoA desaturase 1 (SCD1), glycerol-3-phosphate acyltransferase 1 (GPAT1), acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1), and DGAT2 mRNA
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII significantly reduced hepatic GPAT1 mRNA expression.

    In plain wordsIn diabetic mice, MTII given into the brain lowered activity of the GPAT1 fat-making gene in the liver.

    Peptide
    Melanotan II
    Outcome
    DecreaseHepatic GPAT1 mRNA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    MTII treatment significantly reduced hepatic expression levels of genes encoding lipid biosynthetic enzymes, stearoyl-CoA desaturase 1 (SCD1), glycerol-3-phosphate acyltransferase 1 (GPAT1), acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1), and DGAT2 mRNA
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII significantly reduced hepatic DGAT1 mRNA expression.

    In plain wordsIn diabetic mice, MTII given into the brain lowered activity of the DGAT1 fat-making gene in the liver.

    Peptide
    Melanotan II
    Outcome
    DecreaseHepatic DGAT1 mRNA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    MTII treatment significantly reduced hepatic expression levels of genes encoding lipid biosynthetic enzymes, stearoyl-CoA desaturase 1 (SCD1), glycerol-3-phosphate acyltransferase 1 (GPAT1), acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1), and DGAT2 mRNA
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII significantly reduced hepatic DGAT2 mRNA expression.

    In plain wordsIn diabetic mice, MTII given into the brain lowered activity of the DGAT2 fat-making gene in the liver.

    Peptide
    Melanotan II
    Outcome
    DecreaseHepatic DGAT2 mRNA
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    MTII treatment significantly reduced hepatic expression levels of genes encoding lipid biosynthetic enzymes, stearoyl-CoA desaturase 1 (SCD1), glycerol-3-phosphate acyltransferase 1 (GPAT1), acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1), and DGAT2 mRNA
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, central MTII caused no significant change in serum insulin levels.

    In plain wordsIn diabetic mice, MTII given into the brain did not change blood insulin levels.

    Peptide
    Melanotan II
    Outcome
    No significant changeSerum insulin
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    without significant changes in serum insulin levels, homeostasis model-assessment of insulin resistance (HOMA-IR) and glucose tolerance in STZ-induced diabetic mice.
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, central MTII caused no significant change in HOMA-IR.

    In plain wordsIn diabetic mice, MTII given into the brain did not change insulin resistance scores.

    Peptide
    Melanotan II
    Outcome
    No significant changeHOMA-IR
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    without significant changes in serum insulin levels, homeostasis model-assessment of insulin resistance (HOMA-IR) and glucose tolerance in STZ-induced diabetic mice.
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, central MTII caused no significant change in glucose tolerance.

    In plain wordsIn diabetic mice, MTII given into the brain did not change glucose tolerance.

    Peptide
    Melanotan II
    Outcome
    No significant changeGlucose tolerance
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    without significant changes in serum insulin levels, homeostasis model-assessment of insulin resistance (HOMA-IR) and glucose tolerance in STZ-induced diabetic mice.
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII reduced fatty acid synthase protein levels in the liver.

    In plain wordsIn diabetic mice, MTII given into the brain lowered liver levels of the fat-making enzyme FAS.

    Peptide
    Melanotan II
    Outcome
    DecreaseHepatic FAS protein
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    MTII treatment also reduced fatty acid synthase (FAS) and SCD1 protein levels in the liver of diabetic mice.
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII reduced SCD1 protein levels in the liver.

    In plain wordsIn diabetic mice, MTII given into the brain lowered liver levels of the fat-making enzyme SCD1.

    Peptide
    Melanotan II
    Outcome
    DecreaseHepatic SCD1 protein
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    MTII treatment also reduced fatty acid synthase (FAS) and SCD1 protein levels in the liver of diabetic mice.
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII significantly reduced expression of the lipogenic transcription factor SREBP-1c.

    In plain wordsIn diabetic mice, MTII given into the brain lowered activity of the SREBP-1c fat-making switch gene.

    Peptide
    Melanotan II
    Outcome
    DecreaseHepatic SREBP-1c expression
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Expression levels of genes encoding transcription factors of these lipogenic genes, sterol regulatory element-binding protein 1c (SREBP-1c) and peroxisome proliferator-activated receptor γ2 (PPARγ2) were also significantly reduced by MTII treatment.
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, central MTII significantly reduced expression of the lipogenic transcription factor PPARγ2.

    In plain wordsIn diabetic mice, MTII given into the brain lowered activity of the PPARγ2 fat-making switch gene.

    Peptide
    Melanotan II
    Outcome
    DecreaseHepatic PPARgamma2 expression
    Study

    mousen: not reported in source

    streptozotocin-induced diabetic mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    3 nmol daily · intracerebroventricular · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Expression levels of genes encoding transcription factors of these lipogenic genes, sterol regulatory element-binding protein 1c (SREBP-1c) and peroxisome proliferator-activated receptor γ2 (PPARγ2) were also significantly reduced by MTII treatment.
    1 context sentence
    Summary · context
    Diabetic mice received daily i.c.v. injections of MTII (3 nmol) for 11 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.